Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)

X
Trial Profile

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Cyclophosphamide
  • Indications Interstitial lung diseases
  • Focus Therapeutic Use
  • Acronyms SLSII; The Scleroderma Lung Study II
  • Most Recent Events

    • 08 Dec 2021 Results from Scleroderma Lung Studies (SLS) I and II evaluated the safety and efficacy of cyclophosphamide (SLS I and II) and mycophenolate (SLS II) for the treatment of SSc-ILD published in the Chest
    • 30 Dec 2020 New trial record
    • 12 Dec 2020 Results of a biomarker study using serum samples from this trial assessing predictive significance for longitudinal forced vital capacity percentage of six interferon inducible proteins (IP-10, MIG, MCP-2, B2M, TNFR2, and MIP-3 beta) published in the Arthritis and Rheumatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top